A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma

BACKGROUND: Despite being a highly vascularized tumor, glioblastoma response to anti-vascular endothelial growth factor (VEGF) therapy is transient, possibly because of tumor co-option of preexisting blood vessels and infiltration into surrounding brain. Integrins, which are upregulated after VEGF i...

詳細記述

保存先:
書誌詳細
出版年:Neuro Oncol
主要な著者: Gerstner, Elizabeth R., Ye, Xiaobu, Duda, Dan G., Levine, Michael A., Mikkelsen, Tom, Kaley, Thomas J., Olson, Jeffrey J., Nabors, Burt L., Ahluwalia, Manmeet S., Wen, Patrick Y., Jain, Rakesh K., Batchelor, Tracy T., Grossman, Stuart
フォーマット: Artigo
言語:Inglês
出版事項: Oxford University Press 2015
主題:
Clinical Investigations
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4578584/
https://ncbi.nlm.nih.gov/pubmed/26008604
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nov085
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料